- Home
- AMRN vs THRD Comparison
AMRN vs THRD Comparison
Compare AMRN & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- THRD
- Stock Information
- Founded
- AMRN 1989
- THRD 2019
- Country
- AMRN Ireland
- THRD United States
- Employees
- AMRN N/A
- THRD N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- THRD Health Care
- Exchange
- AMRN Nasdaq
- THRD Nasdaq
- Market Cap
- AMRN 189.2M
- THRD 157.7M
- IPO Year
- AMRN 1993
- THRD 2022
- Fundamental
- Price
- AMRN $0.45
- THRD $3.50
- Analyst Decision
- AMRN Buy
- THRD Hold
- Analyst Count
- AMRN 1
- THRD 3
- Target Price
- AMRN N/A
- THRD $5.00
- AVG Volume (30 Days)
- AMRN 2.1M
- THRD 339.6K
- Earning Date
- AMRN 03-12-2025
- THRD 03-27-2025
- Dividend Yield
- AMRN N/A
- THRD N/A
- EPS Growth
- AMRN N/A
- THRD N/A
- EPS
- AMRN N/A
- THRD N/A
- Revenue
- AMRN $228,614,000.00
- THRD N/A
- Revenue This Year
- AMRN N/A
- THRD N/A
- Revenue Next Year
- AMRN $19.11
- THRD N/A
- P/E Ratio
- AMRN N/A
- THRD N/A
- Revenue Growth
- AMRN N/A
- THRD N/A
- 52 Week Low
- AMRN $0.35
- THRD $3.18
- 52 Week High
- AMRN $1.11
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- AMRN 41.82
- THRD 36.34
- Support Level
- AMRN $0.42
- THRD $3.41
- Resistance Level
- AMRN $0.50
- THRD $3.68
- Average True Range (ATR)
- AMRN 0.04
- THRD 0.14
- MACD
- AMRN 0.00
- THRD 0.09
- Stochastic Oscillator
- AMRN 65.40
- THRD 41.91
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.